LSK Global PS has expertise and experience required for the development lifecycle starting from the establishment of initial development strategy to the strategies for CMC, preclinical study, clinical study, IND/NDA, etc. in the development of medical technology including new drugs
LSK Global PS carries out the customized development strategy satisfying customers’ demands based on the specialized knowledge of extensive new drug developments and the deep understanding of domestic and foreign market environments and regulatory guides.
In addition to the establishment of strategy for new drug development, LSK Global PS provides customers with multidisciplinary services to help them realize the opportunities for new drug development by allowing them to lead a successful product development through organic collaboration with medical advisors, new drug development experts in the medical and industrial worlds, and statisticians.
LSK Global PS can provide prompt and efficient supports to the domestic customers planning overseas expansion and the foreign customers planning to introduce their products into Korea, with its close networks constructed with the worldwide CRO partners in North America, EU, Japan, Taiwan, China, Southeast Asia, Australia, and so on. LSK Global PS is also providing the services of pipeline discovery, license-in & out, and joint clinical development along with clinical trials matching services.
[Updated on 2019.12.31]